阅读说明：本技术 牛磺罗定在制备抗冠状病毒药物中的应用 (Application of taurolidine in preparing anti-coronavirus medicine ) 是由 苏熙尧 李维城 赵喜伍 轩辕浩宇 卢伟 陈强 严庆文 苏忠 于 2020-07-06 设计创作，主要内容包括：牛磺罗定在制备抗冠状病毒药物中的应用,涉及医药技术领域。本发明首次发现牛磺罗定的新用途,即牛磺罗定在抑制冠状病毒、或者在制备抗冠状病毒药物中的应用,其中冠状病毒为HCoV-229E、HCoV-OC43、SARS-CoV、HCoV-NL63、HCoV-HKU1、或者MERS-CoV。牛磺罗定对人体的安全性已经得到临床实践的检测,本发明发现了牛磺罗定对冠状病毒的明显药效,为抗冠状病毒提供了强有力的理论基础和实践基础,具有开发价值和推广意义。本发明对由冠状病毒感染引发的疾病的治疗提供了新的途径。(An application of taurolidine in preparing anti-coronavirus medicine relates to the technical field of medicine. The invention discovers the new application of taurolidine for the first time, namely the application of taurolidine in inhibiting coronavirus or preparing anti-coronavirus medicines, wherein the coronavirus is HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 or MERS-CoV. The safety of the taurolidine to human bodies is detected by clinical practice, the invention discovers the obvious drug effect of the taurolidine to the coronavirus, provides powerful theoretical basis and practical basis for resisting the coronavirus, and has development value and popularization significance. The invention provides a new approach for treating diseases caused by coronavirus infection.)

1. Use of taurolidine for inhibiting coronavirus, wherein the coronavirus is HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, or MERS-CoV.

2. An application of taurolidine in preparing medicine for resisting coronavirus is disclosed, wherein the coronavirus is HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, or MERS-CoV.

3. Use according to claim 2, characterized in that taurolidine is used in the preparation of a medicament against the severe acute respiratory syndrome coronavirus SARS-CoV.

4. Use according to claim 2, characterized in that taurolidine is used in the preparation of a medicament against the middle east respiratory syndrome coronavirus MERS-CoV.

5. The use according to any one of claims 2 to 4, wherein the taurolidine is in the form of an injection, infusion, tablet or capsule.

6. The use of claim 5, wherein the taurolidine is in the form of an infusion solution.

Technical Field

The invention relates to the technical field of medicines, in particular to application of taurolidine in preparing an anti-coronavirus medicine.

Background

Coronaviruses are enveloped RNA viruses with linear single-stranded positive strands in their genome, and are a large group of viruses widely found in nature. The coronavirus has the diameter of about 80-120 nm, the 5 'end of the genome has a methylated cap structure, the 3' end has a poly (A) tail, and the total length of the genome is about 27-32kb, so that the coronavirus is the virus with the largest genome in the currently known RNA viruses. Coronaviruses can be widespread in humans and other mammals, as well as birds, and cause respiratory, digestive, hepatic, and nervous system types of disease. However, no specific drug is approved for treating infection caused by coronavirus, and even aiming at severe acute respiratory tract patients caused by SARS-CoV and MERS-CoV infection, the clinical treatment mainly aims at reducing patient complications. There is therefore a need to develop or discover drugs that can be used to treat infections caused by coronaviruses.

Chinese patents CN101274921A and CN101285813A disclose that Taurolidine (Taurolidine) has a chemical name: 4,4 ' -methylenebis- (tetrahydro-2H-1, 2, 4-thiadiazine) -1,1,1 ', 1 ' tetraoxide with the molecular formula C₇H₁₆N₄O₄S₂The molecular weight is: 284.348, is white or white-like crystalline powder, and has the following chemical formula:

can be synthesized by the following synthetic route:

taurolidine is a broad spectrum antibacterial, antifungal and antiendotoxic drug. Is mainly used for preventing the junior symptoms of patients suffering from various blood stream infections related to the catheter. It can also be used for treating otitis, pleuropneumonia, osteomyelitis, dermatitis, periodontitis, gingivitis, acne, and ulcer. However, no use of taurolidine against coronaviruses has been found so far.

Disclosure of Invention

The invention aims to provide a new application of taurolidine, namely the application of taurolidine in inhibiting coronavirus or preparing anti-coronavirus medicines, wherein the coronavirus is HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 or MERS-CoV.

In particular to the application of the taurolidine in preparing a medicament for resisting severe acute respiratory syndrome coronavirus SARS-CoV.

In particular to the application of the taurolidine in preparing a medicament for resisting middle east respiratory syndrome coronavirus MERS-CoV.

In the technical scheme, the taurolidine is prepared into injection, infusion solution, tablets, capsules and the like, and the infusion solution is preferred.

The invention has the beneficial effects that:

the invention discovers the new application of taurolidine for the first time, namely the application of taurolidine in inhibiting coronavirus or preparing anti-coronavirus medicines, wherein the coronavirus is HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 or MERS-CoV. The safety of the taurolidine to human bodies is detected by clinical practice, the invention discovers the obvious drug effect of the taurolidine to the coronavirus, provides powerful theoretical basis and practical basis for resisting the coronavirus, and has development value and popularization significance. The invention provides a new approach for treating diseases caused by coronavirus infection.

Detailed Description

In order that the nature of the invention may be better understood, the invention will now be described in further detail with reference to specific examples, which are intended to be illustrative of the invention and not to be limiting of the invention. The inhibitory effect of taurolidine on coronavirus was examined at the cellular level below.